398 related articles for article (PubMed ID: 32278373)
1. Regulators split on antimalarials for COVID-19.
Jaffe S
Lancet; 2020 Apr; 395(10231):1179. PubMed ID: 32278373
[No Abstract] [Full Text] [Related]
2. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
Malviya A
Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
[No Abstract] [Full Text] [Related]
3. COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
Halm MA
Am J Crit Care; 2020 Nov; 29(6):489-492. PubMed ID: 32839815
[No Abstract] [Full Text] [Related]
4. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
Oren O; Yang EH; Gluckman TJ; Michos ED; Blumenthal RS; Gersh BJ
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008688. PubMed ID: 32436730
[No Abstract] [Full Text] [Related]
5. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
Kamp TJ; Hamdan MH; January CT
J Am Heart Assoc; 2020 Jun; 9(12):e016887. PubMed ID: 32463308
[No Abstract] [Full Text] [Related]
6. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
Keshtkar-Jahromi M; Bavari S
Am J Trop Med Hyg; 2020 May; 102(5):932-933. PubMed ID: 32247318
[No Abstract] [Full Text] [Related]
7. Living evidence in response to controversies about the use of antimalarials in COVID-19.
Santillán-García A; Bravo-Jeria R; Verdugo-Paiva F; Rada G
Rev Esp Cardiol (Engl Ed); 2020 Aug; 73(8):693-694. PubMed ID: 32536565
[No Abstract] [Full Text] [Related]
8. [Potential harms associated with 4-aminoquinoline treatment].
Svensson M
Lakartidningen; 2020 Apr; 117():. PubMed ID: 32365215
[TBL] [Abstract][Full Text] [Related]
9. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
[TBL] [Abstract][Full Text] [Related]
10. Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.
White CM; Hernandez AV
J Clin Pharmacol; 2020 Aug; 60(8):949-953. PubMed ID: 32530493
[No Abstract] [Full Text] [Related]
11. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
12. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Yazdany J; Kim AHJ
Ann Intern Med; 2020 Jun; 172(11):754-755. PubMed ID: 32232419
[TBL] [Abstract][Full Text] [Related]
13. Drug Evaluation during the Covid-19 Pandemic.
Rome BN; Avorn J
N Engl J Med; 2020 Jun; 382(24):2282-2284. PubMed ID: 32289216
[No Abstract] [Full Text] [Related]
14. [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?].
Defoort-Dhellemmes S
J Fr Ophtalmol; 2020 Jun; 43(6):548-549. PubMed ID: 32451138
[No Abstract] [Full Text] [Related]
15. Of chloroquine and COVID-19.
Touret F; de Lamballerie X
Antiviral Res; 2020 May; 177():104762. PubMed ID: 32147496
[TBL] [Abstract][Full Text] [Related]
16. What is the role of rheumatologists in the era of COVID-19?
Marotto D; Sarzi-Puttini P
Autoimmun Rev; 2020 Jun; 19(6):102539. PubMed ID: 32251716
[No Abstract] [Full Text] [Related]
17. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
Vollaard A; Gieling EM; van der Linden PD; Sinha B; de Boer MGJ
Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749808
[TBL] [Abstract][Full Text] [Related]
18. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
Jakhar D; Kaur I
Nat Med; 2020 May; 26(5):632. PubMed ID: 32269358
[No Abstract] [Full Text] [Related]
19. Does hydroxychloroquine combat COVID-19? A timeline of evidence.
Alia E; Grant-Kels JM
J Am Acad Dermatol; 2020 Jul; 83(1):e33-e34. PubMed ID: 32283236
[No Abstract] [Full Text] [Related]
20. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
Peschken CA
J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064
[No Abstract] [Full Text] [Related]
[Next] [New Search]